Cedar Brook Financial Partners’s AbCellera Biologics ABCL Stock Holding History

Cedar Brook Financial Partners’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-39,668	Closed	-$180K	–	31
2024 Q1	$180K	Hold	39,668	–	–	0.04%	425
2023 Q4	$216K	Buy	39,668 +9,418	+31%	+$43.6K	0.05%	369
2023 Q3	$139K	Buy	30,250 +5,000	+20%	+$30.4K	0.04%	367
2023 Q2	$163K	Buy	25,250 +1,285	+5%	+$8.77K	0.04%	391
2023 Q1	$181K	Hold	23,965	–	–	0.05%	372
2022 Q4	$243K	Buy	23,965 +2,000	+9%	+$23.1K	0.07%	305
2022 Q3	$217K	Buy	21,965 +1,000	+5%	+$11K	0.07%	305
2022 Q2	$223K	Buy	20,965 +4,000	+24%	+$33.9K	0.07%	303
2022 Q1	$165K	Buy	16,965 +5,250	+45%	+$49.7K	0.04%	367
2021 Q4	$168K	Buy	+11,715	New	+$178K	0.04%	369

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Cedar Brook Financial Partners's ABCL Position: Q2 2024 in Review

Cedar Brook Financial Partners sold out of AbCellera Biologics (ABCL) in Q2 2024, closing a stake of 39,668 shares — an estimated $180K sold.

Cedar Brook Financial Partners first reported a position in ABCL in Q4 2021 and held it in 10 quarters. The position peaked at $243K in Q4 2022. 147 funds tracked by Wall St. Rank hold ABCL as of Q2 2024.

Cedar Brook Financial Partners reported no remaining AbCellera Biologics position as of Q2 2024 after selling out during the quarter.
Cedar Brook Financial Partners sold 39,668 AbCellera Biologics shares in Q2 2024, an estimated $180K.
Cedar Brook Financial Partners first reported a position in AbCellera Biologics in Q4 2021 and held it in 10 quarters.
Cedar Brook Financial Partners's AbCellera Biologics position peaked at $243K in Q4 2022.
147 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2024.

Based on Cedar Brook Financial Partners's 13F filing for Q2 2024, filed 15 Jul 2024.